stella
beta
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) — Stella
Recruiting
Back to Metastatic Castration Resistant Prostate Cancer (mCRPC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(4 sites)
United States
City of Hope, Duarte, California
USC Norris Comprehensive Cancer Center, Los Angeles, California
University of Iowa and Holden Comprehensive Cancer Center, Iowa City, Iowa
Perlmutter Cancer Center - NYU Langone Health, New York, New York
View full record on ClinicalTrials.gov